A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
Status:
Completed
Trial end date:
2018-08-14
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy and safety of KHK4827 in
subjects with moderate to severe plaque psoriasis randomized in a double-blind manner to
receive KHK4827 or placebo for 12 weeks
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Korea Co., Ltd. Kyowa Kirin Korea Co., Ltd.